ABBOTT LABORATORIES EVP and CFO Philip P. Boudreau forfeited 388 shares at $110.36 per share, leaving him with 70,784 shares after the transaction. The disclosed ownership figure gives investors a precise view of Boudreau’s remaining Abbott Equity position following the Sep. 1, 2026 transaction.
Key Highlights
- Philip P. Boudreau serves as ABBOTT LABORATORIES’ executive vice president and chief financial officer.
- Each forfeited share carried a reported value of $110.36.
- According to the filing, Philip Boudreau forfeited 388 ABBOTT LABORATORIES shares in the reported transaction.
ABBOTT LABORATORIES (NYSE: ABT) executive vice president and chief financial officer Philip P. Boudreau forfeited 388 shares at $110.36 per share, leaving him with 70,784 shares after the transaction. The transaction occurred on Sep. 1, 2026.
Abbott CFO’s Remaining Equity Position
Boudreau’s post-transaction ownership stood at 70,784 ABBOTT LABORATORIES shares. The reported transaction involved 388 shares. Each share was valued at $110.36. Philip P. Boudreau holds the company’s executive vice president and chief financial officer roles.
FAQs
Q: How many Abbott Laboratories shares did Philip Boudreau forfeit?
A: According to the filing, Philip Boudreau forfeited 388 ABBOTT LABORATORIES shares in the reported transaction. The filing lists the shares at $110.36 per share.
Q: How many Abbott shares does Philip Boudreau own after the transaction?
A: Philip Boudreau owned 70,784 ABBOTT LABORATORIES shares following the transaction. He serves as the company’s executive vice president and chief financial officer.
Q: When did the Abbott Laboratories share forfeiture occur?
A: The ABBOTT LABORATORIES share forfeiture occurred on Sep. 1, 2026. The transaction involved 388 shares held by Philip P. Boudreau.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.